TrialPath

Find a study

Browse recruiting studies near you — free to check, always your choice.

Match me to a study

561 studies

Recruiting now, in plain language. Every study is watched over by an independent ethics board.

ListMap
Weight & metabolicPeptide & GLP-1Mental healthLungs & breathingHeart & circulationKidneyBrain & memoryBlood disordersImmune & autoimmuneSkin

150 studies on the map

Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS) — Phoenix Children's Hospital, PhoenixStudy to Evaluate Safety, Efficacy and Pharmacokinetics (PK) of a Modified Regimen of Ublituximab — TG Therapeutics Investigational Trial Site, BirminghamA Study to Find Out How EMPAgliflozin is Tolerated and if it Helps Children and Adolescents With Chronic KIDNEY Disease (EMPA-KIDNEY® Kids) — University of Alabama at Birmingham, BirminghamEASi-KIDNEY™ (The Studies of Heart & Kidney Protection With BI 690517 in Combination With Empagliflozin) — Apogee Clinical Research, HuntsvilleA Study to Evaluate How Well Etavopivat Works in People With Sickle Cell Disease — Uni of Alabama at Birmingham, BirminghamEfficacy and Safety of Remibrutinib After Switching From Ocrelizumab in Participants Living With Relapsing Multiple Sclerosis. — Perseverance Research Center, ScottsdaleATHN Transcends: A Natural History Study of Non-Neoplastic Hematologic Disorders — Arizona Hemophilia and Thrombosis Treatment Center at Phoenix Children's Hospital, PhoenixA Research Study Looking at Long-term Treatment With Etavopivat in People With Sickle Cell Disease or Thalassaemia — Univ of Alabama Birmingham, BirminghamA Study to Evaluate the Efficacy and Safety of Remibrutinib in Secondary Progressive Multiple Sclerosis — Alabama Neurology Associates PC, BirminghamComparing the Effectiveness of Matched Related Donor Hematopoietic Stem Cell Transplantation to Disease Modifying Therapy in Pediatric Patients With Sickle Cell Disease — Children's of Alabama (MRD-HCT), BirminghamA Study to Learn More About How Well the Study Treatment Finerenone Works, How Safe it is, How it Moves Into, Through, and Out of the Body, and the Effects it Has on the Body When Taken With an ACE Inhibitor or Angiotensin Receptor Blocker in Children With Chronic Kidney Disease and Proteinuria — Phoenix Children's Hospital | Main - Transplant Department, PhoenixA Study to Learn More About How Safe the Study Treatment Finerenone is in Long-term Use When Taken With an ACE Inhibitor or Angiotensin Receptor Blocker Over 18 Months of Use in Children and Young Adults From 1 to 18 Years of Age With Chronic Kidney Disease and Proteinuria — Phoenix Children's Hospital | Main - Transplant Department, PhoenixA Study Evaluating the Real World Experience of Participants Treated With BRIUMVI® (Ublituximab-xiiy) for Relapsing Multiple Sclerosis (RMS) — TG Therapeutics Investigational Trial Site, BirminghamA Study to Evaluate Safety, Tolerability and Efficacy of AP306 at Fixed Doses in Dialysis Participants With Hyperphosphatemia — R1 Therapeutics Clinical Trial Site, HuntsvilleBest Available Therapy Versus Autologous Hematopoietic Stem Cell Transplant for Multiple Sclerosis (BEAT-MS) — Stanford Multiple Sclerosis Center, Palo AltoA Long-term Follow-up Study in Patients Who Received BEAM-101 — University of Alabama at Birmingham, BirminghamA Phase 2 Study of MZE829 in Adults With APOL1 Kidney Disease — Research Site, DecaturThe Efficacy and Safety of Rilzabrutinib in Participants Aged 10 to 65 Years With Sickle-cell Disease — University of Alabama at Birmingham- Site Number : 8400003, BirminghamTesting an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVO — University of Alabama at Birmingham Cancer Center, BirminghamA Study to Evaluate the Safety, Tolerability, Efficacy, and Drug Levels of CC-97540 in Participants With Relapsing Forms of Multiple Sclerosis, Progressive Forms of Multiple Sclerosis or Refractory Myasthenia Gravis (MG) (Breakfree-2) — Local Institution - 0011, BirminghamA Study to Evaluate BMS-986470 in Healthy Volunteers and Participants With Sickle Cell Disease — University of Alabama at Birmingham, BirminghamMaturation of Arteriovenous Fistula With Automated Sonography Assessments Trial — Trinity Research Group, DothanStudy to Assess the Effects of Angiopoietin-like Protein 3 (ANGPTL3) Inhibition in Adult Participants With Diabetic Kidney Disease — Apogee Clinical Research, LLC, HuntsvilleNon-inferiority Study of Frexalimab Subcutaneous Administration Compared to Intravenous Administration in Adult Participants With Multiple Sclerosis — North Central Neurology Associates- Site Number : 8401100, CullmanSAVE-FistulaS: the SelfWrap-Assisted ArterioVEnous Fistulas Study — AKDHC Bullhead City, Bullhead CityA Study to Evaluate the Safety and Effectiveness of the InnAVasc Arteriovenous Graft for Hemodialysis Access in Patients With End-Stage Renal Disease — AKDHC Medical Research Services, LLC, PhoenixA Phase IIb Study to Evaluate the Effect of Dapagliflozin in Combination With Baxdrostat Compared With Baxdrostat on Albuminuria in Participants With Chronic Kidney Disease and High Blood Pressure. — Research Site, SurpriseA Study to Evaluate the Efficacy, Safety and Tolerability of BMS-986368 in Participants With Multiple Sclerosis Spasticity — Alabama Neurology Associates, BirminghamA Study to Investigate the Efficacy and Safety of Crizanlizumab (5 mg/kg) Compared With Placebo in Adolescent and Adult Sickle Cell Disease Patients Who Experience Frequent Vaso-Occlusive Crises (SPARKLE) — University Of Alabama, BirminghamA Research Study Comparing How Well Different Doses of the Medicine NNC0519-0130 Can Reduce Kidney Damage in People Living With Chronic Kidney Disease — N America Res Inst - San Dimas, San DimasA Study of a Novel Iron-based Phosphate Binder AP301 in Patients With Hyperphosphatemia in the U.S. and China — Renal Consultants Medical Group, Granada HillsFerric Citrate and Chronic Kidney Disease in Children — University of California, Los Angeles, Los AngelesSotagliflozin to Slow Kidney Function Decline in Persons With Type 1 Diabetes and Diabetic Kidney Disease — Stanford University Medical Center, StanfordPeer Support for Adolescents and Emerging Adults With Sickle Cell Pain — University of South Alabama Medical Center, MobileKidney Precision Medicine Project — University of Arizona, TucsonA Phase 2/3 Study in Adult and Adolescent Participants With SCD — Smilow Cancer Hospital, New HavenA Study of Orelabrutinib in Patients With Primary Progressive Multiple Sclerosis — Arizona Neuroscience Research, LLC, PheonixSafety, Efficacy, and Pharmacokinetics of CSL889 in Adults and Adolescents With Sickle Cell Disease During Vaso-Occlusive Crisis — Univ. of California, San Francisco Health Care, OaklandSPYRAL GEMINI Pilot Study — Stanford Hospital and Clinics, StanfordOcrelizumab Discontinuation in Relapsing Multiple Sclerosis — Yale School of Medicine, New HavenProact: A Study of REACT in Subjects With Type 2 Diabetes Mellitus and Chronic Kidney Disease — Nephrology Consultants, HuntsvilleA Trial of Etelcalcetide in Pediatric Participants With Secondary Hyperparathyroidism and Chronic Kidney Disease on Hemodialysis — Childrens Hospital of Los Angeles, Los AngelesStudy to Evaluate the Effectiveness and Safety of Ozanimod Compared to Fingolimod in Children and Adolescents With Relapsing Remitting Multiple Sclerosis — Local Institution - 0114, Loma LindaPost-market Surveillance Study of the BD® WavelinQ™ EndoAVF System — California Institute of Renal Research, La JollaA Study of Orelabrutinib in Patients With Secondary Progressive Multiple Sclerosis — Arizona Neuroscience Research, LLC, PhoenixA Biospecimen Collection Study to Identify the Targets of Disease-Reactive T Cells in Patients With Autoimmune Disease — Knowledge Research Center, OrangeRecruitment and Engagement in Care to Impact Practice Enhancement (RECIPE) for Sickle Cell Disease — University of Alabama, Birmingham (UAB), BirminghamA Phase III Renal Outcomes and Cardiovascular Mortality Study to Investigate the Efficacy and Safety of Baxdrostat in Combination With Dapagliflozin in Participants With Chronic Kidney Disease and High Blood Pressure — Research Site, FairhopeA Study to Assess Bioequivalence of Two Subcutaneous (SC) Formulations of Ocrelizumab in Participants With Multiple Sclerosis (MS) — Profound Research, LLC, CarlsbadAn Open-label Study of AZD0120 in Adults With Multiple Sclerosis — Research Site, TucsonIncremental Hemodialysis: The TwoPlus Trial — University of Florida, JacksonvilleSAfety of Regional Citrate Anticoagulation (SARCA Study) — John L. McClellan Memorial Veterans' Hospital, Little RockAchieving Understanding of the Natural History of Sickle Cell Trait (AUNT) — University of Alabama, BirminghamCSP #2026 - Beta Blocker Dialyzability on Cardiovascular Outcomes — VA Long Beach Healthcare System, Long Beach, CA, Long BeachPivotal Study of the Velocity™ pAVF System — Trinity Research Group, DothanAn Observational Extension Study for Adult Patients Treated in Study R5459-RT-1944 Who Receive a Kidney Transplant — Cedars-Sinai Medical Center, Los AngelesPost Market Study for VasQ, an External Support Implant for Arteriovenous Fistula — Fresenius Vascular Care Long Beach, Long BeachEASi-PROTKT™ - A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular Disease — Pinnacle Research Group, LLC, AnnistonRollover Study for Patients With Sickle Cell Disease Who Have Completed a Prior Novartis-Sponsored Crizanlizumab Study — University Of Alabama, BirminghamA Study to Evaluate the Safety (Compared to Iron Sucrose), Efficacy and Pharmacokinetics of Ferumoxytol for the Treatment of Iron Deficiency Anemia (IDA) in Pediatric Subjects With Chronic Kidney Disease (CKD) — Memorial Healthcare System, HollywoodImplementation pRogram to Improve Screening and Management for CKD in Diabetes (IRIS-CKD) (Program 2) — University of Alabama, BirminghamImplementation pRogram to Improve Screening and Management for CKD in Diabetes (Program 1) (IRIS-CKD) — University of Alabama, BirminghamPReSeRVE-HD: Observational Study of the Merit HeRO® Graft and Super HeRO® in Patients on Hemodialysis — MedStar Washington Hospital Center, Washington D.C.A Phase 1b, Open-Label Study of DISC-3405 in Participants With Sickle Cell Disease (SCD) — University of Alabama at Birmingham, BirminghamDissemination of the Donor Application: Utilizing Social Media to Identify Potential Live Organ Donors — Scripps Green Hospital, San DiegoA Phase I/II Study of ITU512 in Healthy Participants and Patients With Sickle Cell Disease — University of Alabama Birmingham, BirminghamThe SetPoint System as a Pro-Remyelination Therapy for Relapsing-Remitting Multiple Sclerosis: A Pilot Study — Shepherd Center, AtlantaCare in Multiple Sclerosis (MS) — University of Alabama at Birmingham, BirminghamConfirmatory Trial for Alleviating Fatigue in Multiple Sclerosis — Washington VA Medical Center, Washington D.C.A Study to Investigate the Safety, Tolerability, and Processing by the Body of Intravenous and Subcutaneous RO7121932 Administration in Participants With Multiple Sclerosis — Stanford University Medical Center, StanfordOpen-label Extension Study of Zigakibart in Adults With IgA Nephropathy. — Colorado Kidney Care Nephrology, DenverA Study to Investigate Multiple Sclerosis Relapse Prevention With mRNA-1195 Compared With Placebo in Participants Aged 18 to ≤55 Years — Boston Clinical Trials Inc - Internal Medicine, BostonA Study to Investigate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Pharmacodynamics of a New Subcutaneous Formulation of Ocrelizumab in Participants With Multiple Sclerosis — Profound Research, LLC, CarlsbadA Study to Evaluate the Safety and Therapeutic Activity of GI-102 As a Single Agent and in Combination with Conventional Anti-cancer Drugs, Pembrolizumab or Trastuzumab Deruxtecan(T-DXd) in Patients with Advanced Solid Tumors (KEYNOTE-G08) — Mayo Clinic in Arizona, ScottsdaleMinimizing Toxicity in HLA-identical Sibling Donor Transplantation for Children With Sickle Cell Disease — Children's National Health System, Washington D.C.Incremental Hemodialysis for Veterans in the First Year of Dialysis (IncHVets) — VA Long Beach Healthcare System, Long Beach, CA, Long BeachZinc Supplementation in Sickle Cell Disease: A Precursor to the Think Zinc for Bones Trial — UCSF Benioff Children's Hospital Oakland, OaklandA Study to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD4248 in Healthy Participants and Participants With Chronic Kidney Disease and Type 2 Diabetes and to Assess Home Measurements of Creatinine in a Non Interventional Cohort — Research Site, GlendaleEmpagliflozin Treatment in Kidney Transplant Recipients — Edward Hines Jr. VA Hospital, Hines, IL, HinesModa-flx Hemodialysis System™ Under Professional Care Settings by Trained Individuals and At Home by Participants — North America Research Institute, San DimasBreathe Easier With Tadalafil Therapy for Dyspnea in COPD-PH — Rocky Mountain Regional VA Medical Center, Aurora, CO, AuroraSafety of Anumigilimab (CSL324) in Adults With Sickle Cell Disease (SCD) — UAMS Medical Center, Little RockA Study Evaluating the Presence and Concentration of BRIUMVI™ (Ublituximab) in Breast Milk — PROVIDE Virtual Research Coordination Center, San FranciscoCollecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection — Anchorage Associates in Radiation Medicine, AnchorageSafety & Efficacy of DCR-PHXC in Patients With PH1 and ESRD — Clinical Trial Site, San FranciscoStudy of a Single Dose of a 21-valent Pneumococcal Conjugate Vaccine in Children and Adolescents With Sickle Cell Disease — Site # 8400006, AtlantaSickle Cell Clinical Research and Intervention Program — Children's Hospital of Illinois at OSF-Saint Francis Medical Center, PeoriaGene Correction in Autologous CD34+ Hematopoietic Stem Cells (HbS to HbA) to Treat Severe Sickle Cell Disease — Children's Hospital Los Angeles, Los AngelesA Study Evaluating the Safety and Efficacy of KITE-363 in Relapsed/Refractory Autoimmune Neurologic Diseases — Stanford Neuroscience Health Center, Palo AltoRaDIANT Health Systems Intervention — Piedmont Transplant Institute, AtlantaCooperative Assessment of Late Effects for SCD Curative Therapies — Children's National Medical Center, Washington D.C.Genes and Environment in Multiple Sclerosis — National Institute of Neurological Disorders and Stroke, BethesdaShingrix in Renal Transplant Recipients — University of Colorado Anschutz, AuroraMyeloablative Conditioning, Prophylactic Defibrotide and Haplo AlloSCT for Patients With Sickle Cell Disease — University of California Los Angeles, Los AngelesA Socio-ecological Approach for Improving Self-management in Adolescents With SCD — Nemours Children's Health, WilmingtonRuxolitinib-Enhanced Haplo HCT for Children and Young Adults With Sickle Cell Disease — Children's Hospital of Colorado, AuroraDelivering Patient-Facing Evidence-Based Guidelines Through mHealth to Adults With Sickle Cell Disease — University of Illinois at Chicago, ChicagoReduced Intensity Conditioning and Familial HLA-Mismatched BMT for Non-Malignant Disorders — Yale School of Medicine, New HavenInternational (Pediatric) Peritoneal Biobank — University of Alabama at Birmingham, BirminghamA Study of LY3971297 in Healthy Participants — CenExel ACT, AnaheimREgulatory T Cell Therapy to Achieve Immunosuppression REduction — Mayo Clinic in Arizona, PhoenixEvaluation of Efficacy and Safety of a Single Dose of CTX001 in Participants With Transfusion-Dependent β-Thalassemia and Severe Sickle Cell Disease — New York Presbyterian Hospital - Morgan Stanley Children's Hospital, New YorkStudy of Orellanine in Metastatic Clear-Cell or Papillary Renal Cell Carcinoma — Stanford, Palo AltoClinical Phenotyping Resource and Biobank Core of the Michigan O'Brien Renal Center — University of Michigan Health System, Ann ArborDecellularized Femoral Artery Allograft (Nexeon AVX) Prospective Registry — Infirmary Heath, MobileCombination of Novel Therapies for CKD Comorbid Depression — Stony Brook University Medical Center, Stony BrookSensor-based Congestion ALert for Events in Peritoneal Dialysis (SCALE-PD) — Desert Cities Dialysis, VictorvilleIntegrative Training Program for Pediatric Sickle Cell Pain — Connecticut Children's Medical Center, HartfordTransforming Hemodialysis-Related Vascular Access Education — Johns Hopkins University, BaltimoreKidney Function in People With Cystic Fibrosis in the Era of HEMT — University of Alabama at Birmingham, BirminghamApplying Directly Observed Therapy to Hydroxyurea to Realize Effectiveness — Lurie Children's Hospital, ChicagoSCD Stem Cell Mobilization and Apheresis Using Motixafortide — University of Alabama at Birmingham, BirminghamProspective Evaluation of Sequencing From antiCD-20 Therapies to Ozanimod — University of Colorado Anschutz Medical Campus, AuroraCentral Vein Sign in Multiple Sclerosis Extension Study — Cedars-Sinai Medical Center, Los AngelesPregnancy Exposure Registry for Vumerity (Diroximel Fumarate) — University of Colorado Anschutz Medical Campus, AuroraA Study of Immune Suppression Treatment for People With Sickle Cell Disease or β-Thalassemia Who Are Going to Receive an Allogeneic Hematopoietic Cell Transplantation (HCT) — Memorial Sloan Kettering at Basking Ridge (Consent only), Basking RidgeStudy to Evaluate the Usability and Value of Integrated Digital Solutions in Medical Care of Participants With Multiple Sclerosis — Minneapolis Clinic of Neurology, Golden ValleyMilitary Health and Nutrition Examination Study — Fort Campbell, Fort CampbellAmerican Indian Chronic Renal Insufficiency Cohort Study (AI-CRIC Study) — NIDDK-Phoenix Epidemiology and Clinical Research, PhoenixA Cardiometabolic Health Program Linked With Clinical-Community Support and Mobile Health Telemonitoring to Reduce Health Disparities — Unity Health Care, Washington D.C.Safety, PK and Biodistribution of 18F-OP-801 in Patients With ALS, AD, MS, PD and Healthy Volunteers — UCSF, San FranciscoMultiple Sclerosis Implementation Network (Registry) — Multiple Sclerosis Association of America, Cherry HillSit Less, Interact and Move More (SLIMM) 2 Study — Stanford University, StanfordPuberty, Diabetes, and the Kidneys, When Eustress Becomes Distress (PANTHER Study) — Children's Hospital Colorado, AuroraNAVIGATE Kidney: A Multi-level Intervention to Reduce Kidney Health Disparities — Denver Health and Hospital Authority, DenverOral Iron in Children With Chronic Kidney Disease — Weill Cornell Medicine / New York Presbyterian Hospital, New YorkSodium Bicarbonate and Mitochondrial Energetics in Persons With CKD — University of California Davis Health, SacramentoChronic Kidney Disease in Children Prospective Cohort Study (CKiD) — Children's Mercy Kansas City, Kansas CityExercise and Monitoring With Post-Hospitalization Muscle Atrophy to Sustain Intrinsic Capacity and Strength — Rocky Mountain Regional VA Medical Center, Aurora, CO, AuroraSafety and Efficacy of Empagliflozin in Hemodialysis — Brigham and Women's Hospital, BostonCoQ10 and Exercise for Mitochondrial Dysfunction in Advance Kidney Disease — University of California Davis Health, SacramentoStudy to Evaluate the Safety and Efficacy of the 10 GE Xenokidney in Patients With ESRD — Northwestern Memorial Hospital, ChicagoComparing Surgical and Endovascular Arteriovenous Fistula Creation — UCLA Division of Vascular and Endovascular Surgery Clinic, Los AngelesBone in CKD Alkali Response (BICARb Pilot Trial) — Albert Einstein College of Medicine, The BronxEffect of the Amplifi™ Vein Dilation System on Outflow Vein Dilation and AV Fistula Maturation (AMPLIFI-1) — Brigham Women's Hospital, BostonTechnology Assisted Collaborative Care Intervention to Improve Patient-centered Outcomes in Dialysis Patients — UNM, AlbuquerqueClinical and Biomarker Effects of Depot Medroxyprogesterone Acetate in Females With Sickle Cell Disease — Emory University, AtlantaMULTIsite Feasibility of MUSIc Therapy to Address Quality Of Life in Sickle Cell Disease — UH Seidman Cancer Center Adult SCD Clinic or UH Rainbow Babies and Children's Hospital Sickle Cell Anemia Center, ClevelandTargeting Agonists of Glucagon-like Peptide-1 Receptor for Multiple Sclerosis — Johns Hopkins University, BaltimoreHigh-Intensity, Dynamic-stability Gait Training in People With Multiple Sclerosis — Rehabilitation Hospital of Indiana, IndianapolisTreatment of Participants With Primary or Secondary Progressive Multiple Sclerosis — University of Kansas Medical Center, Kansas CityStudy of the Role of Genetic Modifiers in Hemoglobinopathies — Boston Children's Hospital, BostonSafety, Pharmacokinetics, and Efficacy of AT 1501 in Patients Undergoing Kidney Transplant — University of Cincinnati, CincinnatiObe-cel in Refractory Progressive Forms of Multiple Sclerosis — Stanford University, Redwood CityFeasibility of The Health Integrated Nutrition and Kidney Wellness Program — UPMC Kidney Clinic - Wexford, PittsburghChronic Kidney Disease-Education (CKD-EDU) — UR Medicine Nephrology - Strong West, BrockportCardiovascular Kidney and Metabolic Health Assessment and Patient Empowerment — Fountains Family Care, ChandlerEffect of MitoQ on Platelet Function and Reactive Oxygen Species Generation in Patients With Sickle Cell Anemia — Magee Women's Hospital, PittsburghFood and Fitness With Medicine (FFWM) — Ohio State Healthy Community Center, ColumbusA Novel Digital Tool Physicians Can Use to Prescribe Exercise to Patients With Cardiovascular Disease Risk Factors — UConn Health, Farmington

Showing the 150 nearest — narrow your filters for fewer, closer studies.